2010
DOI: 10.1056/nejmoa1007964
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding. There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI. (Funded by Cogentus Pharmaceuticals; ClinicalTrials.gov number, NCT00557921.).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

15
721
3
41

Year Published

2011
2011
2022
2022

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 1,015 publications
(780 citation statements)
references
References 41 publications
15
721
3
41
Order By: Relevance
“…The major disadvantages are: (1) increased processing time per sample because of the need to generate platelet rich plasma, and (2) increased interoperator variability. The vasodilator-activated phosphoprotein (VASP) test measures the intracellular platelet response to medications inhibiting the platelet P2Y 12 receptor. Like LTA, it is a time-consuming, laboratorybased test that is technically demanding.…”
Section: Measures Of Platelet Functionmentioning
confidence: 99%
See 3 more Smart Citations
“…The major disadvantages are: (1) increased processing time per sample because of the need to generate platelet rich plasma, and (2) increased interoperator variability. The vasodilator-activated phosphoprotein (VASP) test measures the intracellular platelet response to medications inhibiting the platelet P2Y 12 receptor. Like LTA, it is a time-consuming, laboratorybased test that is technically demanding.…”
Section: Measures Of Platelet Functionmentioning
confidence: 99%
“…A small but clinically meaningful interaction with PPI in ACS patients at high ischemic risk in the acute settings cannot be excluded. Treatment with other potent P2Y 12 receptor inhibitors, such as prasugrel and ticagrelor, is not associated with an interaction with PPIs and could be considered in patients at high risk for ischemic events. In patients at risk for peptic ulcer, treatment with effective gastric protection, including PPIs, should not be withheld.…”
Section: Proton-pump Inhibitor (Ppi)-clopidogrel Interactions: Realitmentioning
confidence: 99%
See 2 more Smart Citations
“…18,19 Whether these drugs may reduce the cardiovascular protection by antiplatelet drugs has been discussed, 20 but the randomized COGENT trial showed that in patients treated with aspirin and clopidogrel, proton pump inhibitors reduce GI bleeding complications without increasing cardiovascular event rates. 21 Although bleeding, including GI bleeding, is the most frequent complication of clopidogrel therapy, safety data on the use of clopidogrel obtained from unselected patients are sparse. Clopidogrel remains the second most prescribed drug worldwide, 22 and investigating clopidogrel-related bleeding is important.…”
Section: Introductionmentioning
confidence: 99%